Tag: DCBs

‘No signal of increased risk of long-term mortality’ with paclitaxel-coated Luminor...

An ad hoc, two-year analysis of the EffPac study found no signal of increased risk of long-term mortality, nor any adverse events, within two years...

IN.PACT Admiral DCB shows ‘significant advantage’ over uncoated devices in fempop...

The IN.PACT Admiral drug-coated balloon (DCB) demonstrated a significant advantage in overall survival, amputation-free survival and target-lesion revascularization after femoropopliteal artery treatment through four-year...

Six-month IN.PACT AV Access results show superiority of DCB angioplasty

Just-published six-month results of the IN.PACT AV Access study show that drug-coated balloon (DCB) angioplasty is superior to standard angioplasty for the treatment of...

MHRA: Warning to be added to paclitaxel device IFUs in Europe

In a new field safety notice, the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) states that a warning and clinical summary section will be...
Richard Neville

Drug-coated technology question aired during SAVS opening session

PALM BEACH, Fla.—Discussion of the drug-coated technology issue was piqued during the opening session of the Southern Association for Vascular Surgery (SAVS) annual meeting...

SVS president presents point-by-point defense of Society position on paclitaxel controversy

NEW YORK—Kim Hodgson, MD, president of the Society for Vascular Surgery, delivered a robust defense of the SVS position on the drug-coated balloon (DCB)...